All In Biotech

Drug Trial Radar · NCT00087490

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Linezolid in the Treatment of Subjects With Complicated Skin and Soft Tissue Infections Proven to be Due to Methicillin-Resistant Staphylococcus Aureus

Last checked: Nov 20, 2026Latest source record: Aug 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,077 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,077

Actual

Start

Oct 2004

Primary completion

Jul 2007

Study completion Jul 2007

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 13, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects

Conditions

  • Skin/Soft Tissue Infections
  • Methicillin Resistant Staphylococcus Aureus (MRSA)

Interventions

  • linezolidDrug

  • vancomycinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) PopulationTime frame: EOS (6 to 28 days after the last dose of study drug)

Locations

126 sites in 16 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Montgomery, Alabama

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Palm Springs, California

  • Pfizer Investigational Site

    Rancho Mirage, California

  • Pfizer Investigational Site

    San Pedro, California

  • Pfizer Investigational Site

    Santa Fe Springs, California

  • Pfizer Investigational Site

    Sylmar, California

  • Pfizer Investigational Site

    Torrance, California

  • Pfizer Investigational Site

    Torrance, California

  • Pfizer Investigational Site

    Torrance, California

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Denver, Colorado

  • Pfizer Investigational Site

    Hartford, Connecticut

  • Pfizer Investigational Site

    Hartford, Connecticut

  • Pfizer Investigational Site

    New Haven, Connecticut

  • Pfizer Investigational Site

    New Haven, Connecticut

  • Pfizer Investigational Site

    Atlantis, Florida

  • Pfizer Investigational Site

    Melbourne, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Pensacola, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Augusta, Georgia

  • Pfizer Investigational Site

    Blue Ridge, Georgia

  • Pfizer Investigational Site

    Honolulu, Hawaii

  • Pfizer Investigational Site

    Honolulu, Hawaii

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Decatur, Illinois

  • Pfizer Investigational Site

    Hines, Illinois

  • Pfizer Investigational Site

    Maywood, Illinois

  • Pfizer Investigational Site

    North Chicago, Illinois

  • Pfizer Investigational Site

    Northlake, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Springfield, Illinois

  • Pfizer Investigational Site

    Iowa City, Iowa

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    New Orleans, Louisiana

  • Pfizer Investigational Site

    Baltimore, Maryland

Showing 40 of 126 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.